全文获取类型
收费全文 | 24522篇 |
免费 | 1957篇 |
国内免费 | 101篇 |
专业分类
耳鼻咽喉 | 290篇 |
儿科学 | 723篇 |
妇产科学 | 456篇 |
基础医学 | 2741篇 |
口腔科学 | 485篇 |
临床医学 | 2545篇 |
内科学 | 5316篇 |
皮肤病学 | 399篇 |
神经病学 | 2363篇 |
特种医学 | 749篇 |
外国民族医学 | 2篇 |
外科学 | 3870篇 |
综合类 | 559篇 |
一般理论 | 26篇 |
预防医学 | 2089篇 |
眼科学 | 652篇 |
药学 | 1626篇 |
中国医学 | 33篇 |
肿瘤学 | 1656篇 |
出版年
2021年 | 395篇 |
2020年 | 265篇 |
2019年 | 421篇 |
2018年 | 464篇 |
2017年 | 348篇 |
2016年 | 339篇 |
2015年 | 455篇 |
2014年 | 621篇 |
2013年 | 963篇 |
2012年 | 1412篇 |
2011年 | 1392篇 |
2010年 | 825篇 |
2009年 | 729篇 |
2008年 | 1280篇 |
2007年 | 1399篇 |
2006年 | 1415篇 |
2005年 | 1405篇 |
2004年 | 1323篇 |
2003年 | 1248篇 |
2002年 | 1204篇 |
2001年 | 383篇 |
2000年 | 335篇 |
1999年 | 363篇 |
1998年 | 255篇 |
1997年 | 223篇 |
1996年 | 217篇 |
1995年 | 210篇 |
1994年 | 184篇 |
1993年 | 173篇 |
1992年 | 268篇 |
1991年 | 228篇 |
1990年 | 267篇 |
1989年 | 204篇 |
1988年 | 228篇 |
1987年 | 217篇 |
1986年 | 206篇 |
1985年 | 202篇 |
1984年 | 217篇 |
1983年 | 216篇 |
1982年 | 222篇 |
1981年 | 207篇 |
1980年 | 217篇 |
1979年 | 210篇 |
1978年 | 166篇 |
1977年 | 134篇 |
1976年 | 142篇 |
1975年 | 124篇 |
1974年 | 155篇 |
1973年 | 131篇 |
1972年 | 121篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
1.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
2.
3.
Diagnostic accuracy of laboratory and ultrasound findings in patients with a non-visualized appendix
Laurie Malia Jesse J. Sturm Sharon R. Smith R. Timothy Brown Brendan Campbell Henry Chicaiza 《The American journal of emergency medicine》2019,37(5):879-883
Ultrasound (US) and laboratory testing are initial diagnostic tests for acute appendicitis. A diagnostic dilemma develops when the appendix is not visualized on US. Objective: To determine if specific US findings and/or laboratory results predict acute appendicitis when the appendix is not visualized. Methods: A prospective study was conducted on children (birth-18?yrs) presenting to the pediatric emergency department with suspected acute appendicitis who underwent right lower quadrant US.Children with previous appendectomy, US at another facility, or eloped were excluded. US findings analyzed: inflammatory changes, right lower quadrant and lower abdominal fluid, tenderness during US exam and lymph nodes. Diagnoses were confirmed via surgical pathology. Results 1252 subjects were enrolled, 60.8% (762) had appendix visualized and 39.1% (490) did not. In children where the appendix was not seen, 6.7% [33] were diagnosed with appendicitis. Among patients with a non-visualized appendix, the likelihood of appendicitis was significantly greater if: inflammatory changes in the RLQ (OR 18.0, 95% CI 4.5–72.1), CRP >0.5?mg/dL (OR 2.64, 95% CI 1.0–6.8), or WBC?>?10 (OR 4.36, 95% CI 1.66–11.58). Duration of abdominal pain >3?days was significantly less likely associated with appendicitis in this model (OR 0.34, 95% CI 0.003–0.395). Combined, the absence inflammatory changes, CRP?<?0.5?mg/dL, WBC?<?10, and pain, ≤3?days had a NPV of 94.0%. Conclusion When the appendix is not visualized on US, predictors for appendicitis include the presence of inflammatory changes in the RLQ, an elevated WBC/CRP and abdominal pain <3?days. 相似文献
4.
5.
6.
Patel Mallika P. Kirkpatrick John P. Johnson Margaret O. Healy Patrick Herndon James E. Lipp Eric S. Miller Elizabeth S. Desjardins Annick Randazzo Dina Friedman Henry S. Ashley David M. Peters Katherine B. 《Journal of neuro-oncology》2020,147(2):477-483
Journal of Neuro-Oncology - Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin’s lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of... 相似文献
7.
8.
9.
10.